Document is current
Any future updates will be listed below
-
Authors
Ferreira, Ana Catarina
Hemmer, Brittany M. https://orcid.org/0000-0003-0898-5142
Philippi, Sarah M. https://orcid.org/0000-0002-4206-7575
Grau-Perales, Alejandro B.
Rosenstadt, Jacob L.
Liu, Hanxiao
Zhu, Jeffrey D. https://orcid.org/0000-0001-8578-3574
Kareva, Tatyana
Ahfeldt, Tim
Varghese, Merina https://orcid.org/0000-0002-1517-3903
Hof, Patrick R.
Castellano, Joseph M. https://orcid.org/0000-0002-8026-6292
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG072300, AG061382, AG061382-S1, AG049688)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
- License Information
-
More Information
Article History
Received: 9 February 2023
Revised: 27 September 2023
Accepted: 6 October 2023
First Online: 2 November 2023
Competing interests
: JMC is listed as a co-inventor on patents for treating aging-associated conditions, including the use of young plasma administration (US10688130B2) or youth-associated protein TIMP2 (US10617744B2), the latter of which is licensed to Alkahest, Inc.
